{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:46:37Z","timestamp":1790804797809,"version":"4.1.0"},"publisher-location":"Cham","reference-count":72,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319557793","type":"print"},{"value":"9783319557809","type":"electronic"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1007\/978-3-319-55780-9_2","type":"book-chapter","created":{"date-parts":[[2017,7,28]],"date-time":"2017-07-28T12:13:52Z","timestamp":1501244032000},"page":"9-21","source":"Crossref","is-referenced-by-count":63,"title":["Biochemical and Clinical Aspects of Hereditary Tyrosinemia Type 1"],"prefix":"10.1007","author":[{"given":"Genevi\u00e8ve","family":"Morrow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Tanguay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,29]]},"reference":[{"issue":"11","key":"2_CR1","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.clinbiochem.2004.07.006","volume":"37","author":"P Allard","year":"2004","unstructured":"Allard P, Grenier A, Korson MS, Zytkovicz TH (2004) Newborn screening for hepatorenal tyrosinemia by tandem mass spectrometry: analysis of succinylacetone extracted from dried blood spots. Clin Biochem 37(11):1010\u20131015. doi:S0009-9120(04)00202-4","journal-title":"Clin Biochem"},{"key":"2_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/8904_2014_363","volume":"19","author":"F Angileri","year":"2015","unstructured":"Angileri F, Bergeron A, Morrow G, Lettre F, Gray G, Hutchin T, Ball S (2015) Geographical and ethnic distribution of mutations of the fumarylacetoacetate hydrolase gene in hereditary tyrosinemia type 1. JIMD Rep 19:45\u201358. doi: 10.1007\/8904_2014_363","journal-title":"JIMD Rep"},{"issue":"1","key":"2_CR3","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1542\/peds.105.1.e10","volume":"105","author":"DA Applegarth","year":"2000","unstructured":"Applegarth DA, Toone JR, Lowry RB (2000) Incidence of inborn errors of metabolism in British Columbia, 1969\u20131996. Pediatrics 105(1):e10","journal-title":"Pediatrics"},{"issue":"1","key":"2_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10545-012-9482-1","volume":"36","author":"DC Bartlett","year":"2013","unstructured":"Bartlett DC, Preece MA, Holme E, Lloyd C, Newsome PN, McKiernan PJ (2013) Plasma succinylacetone is persistently raised after liver transplantation in tyrosinaemia type 1. J Inherit Metab Dis 36(1):15\u201320. doi: 10.1007\/s10545-012-9482-1","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"2_CR5","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s10545-014-9683-x","volume":"37","author":"DC Bartlett","year":"2014","unstructured":"Bartlett DC, Lloyd C, McKiernan PJ, Newsome PN (2014) Early nitisinone treatment reduces the need for liver transplantation in children with tyrosinaemia type 1 and improves post-transplant renal function. J Inherit Metab Dis 37(5):745\u2013752. doi: 10.1007\/s10545-014-9683-x","journal-title":"J Inherit Metab Dis"},{"issue":"18","key":"2_CR6","doi-asserted-by":"publisher","first-page":"15284","DOI":"10.1074\/jbc.M007621200","volume":"276","author":"RL Bateman","year":"2001","unstructured":"Bateman RL, Bhanumoorthy P, Witte JF, McClard RW, Grompe M, Timm DE (2001) Mechanistic inferences from the crystal structure of fumarylacetoacetate hydrolase with a bound phosphorus-based inhibitor. J Biol Chem 276(18):15284\u201315291. doi: 10.1074\/jbc.M007621200","journal-title":"J Biol Chem"},{"issue":"2","key":"2_CR7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1042\/BJ20060961","volume":"402","author":"RL Bateman","year":"2007","unstructured":"Bateman RL, Ashworth J, Witte JF, Baker LJ, Bhanumoorthy P, Timm DE, Hurley TD, Grompe M, McClard RW (2007) Slow-onset inhibition of fumarylacetoacetate hydrolase by phosphinate mimics of the tetrahedral intermediate: kinetics, crystal structure and pharmacokinetics. Biochem J 402(2):251\u2013260. doi: 10.1042\/BJ20060961","journal-title":"Biochem J"},{"issue":"9","key":"2_CR8","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1074\/jbc.M506804200","volume":"281","author":"A Bergeron","year":"2006","unstructured":"Bergeron A, Jorquera R, Orejuela D, Tanguay RM (2006) Involvement of endoplasmic reticulum stress in hereditary tyrosinemia type I. J Biol Chem 281(9):5329\u20135334. doi:M506804200","journal-title":"J Biol Chem"},{"issue":"5","key":"2_CR9","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s10545-012-9556-0","volume":"36","author":"YT Bliksrud","year":"2013","unstructured":"Bliksrud YT, Ellingsen A, Bjoras M (2013) Fumarylacetoacetate inhibits the initial step of the base excision repair pathway: implication for the pathogenesis of tyrosinemia type I. J Inherit Metab Dis 36(5):773\u2013778. doi: 10.1007\/s10545-012-9556-0","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"2_CR10","first-page":"302","volume":"47","author":"M Braekeleer De","year":"1990","unstructured":"De Braekeleer M, Larochelle J (1990) Genetic epidemiology of hereditary tyrosinemia in Quebec and in Saguenay-Lac-St-Jean. Am J Hum Genet 47(2):302\u2013307","journal-title":"Am J Hum Genet"},{"key":"2_CR11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1750-1172-8-8","volume":"8","author":"C Laet de","year":"2013","unstructured":"de Laet C, Dionisi-Vici C, Leonard JV, McKiernan P, Mitchell G, Monti L, de Baulny HO, Pintos-Morell G, Spiekerkotter U (2013) Recommendations for the management of tyrosinaemia type 1. Orphanet J Rare Dis 8:8. doi:1750-1172-8-8","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"2_CR12","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0046-8177(03)00406-4","volume":"34","author":"SI Demers","year":"2003","unstructured":"Demers SI, Russo P, Lettre F, Tanguay RM (2003) Frequent mutation reversion inversely correlates with clinical severity in a genetic liver disease, hereditary tyrosinemia. Hum Pathol 34(12):1313\u20131320. doi:S0046817703004064","journal-title":"Hum Pathol"},{"issue":"13","key":"2_CR13","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1128\/MCB.22.13.4943-4951.2002","volume":"22","author":"JM Fernandez-Canon","year":"2002","unstructured":"Fernandez-Canon JM, Baetscher MW, Finegold M, Burlingame T, Gibson KM, Grompe M (2002) Maleylacetoacetate isomerase (MAAI\/GSTZ)-deficient mice reveal a glutathione-dependent nonenzymatic bypass in tyrosine catabolism. Mol Cell Biol 22(13):4943\u20134951","journal-title":"Mol Cell Biol"},{"issue":"2","key":"2_CR14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1665-2681(19)30890-7","volume":"13","author":"C Fernandez-Lainez","year":"2014","unstructured":"Fernandez-Lainez C, Ibarra-Gonzalez I, Belmont-Martinez L, Monroy-Santoyo S, Guillen-Lopez S, Vela-Amieva M (2014) Tyrosinemia type I: clinical and biochemical analysis of patients in Mexico. Ann Hepatol 13(2):265\u2013272. doi:1090941","journal-title":"Ann Hepatol"},{"issue":"2","key":"2_CR15","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s002470050551","volume":"29","author":"S Forget","year":"1999","unstructured":"Forget S, Patriquin HB, Dubois J, Lafortune M, Merouani A, Paradis K, Russo P (1999) The kidney in children with tyrosinemia: sonographic, CT and biochemical findings. Pediatr Radiol 29(2):104\u2013108","journal-title":"Pediatr Radiol"},{"key":"2_CR16","first-page":"69","volume":"85","author":"AE Garrod","year":"1902","unstructured":"Garrod AE (1902) About alkaptonuria. Med-Chir Trans 85:69\u201378","journal-title":"Med-Chir Trans"},{"issue":"7","key":"2_CR17","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/clinchem\/22.7.1001","volume":"22","author":"A Grenier","year":"1976","unstructured":"Grenier A, Belanger L, Laberge C (1976) alpha1-Fetoprotein measurement in blood spotted on paper: discriminating test for hereditary tyrosinemia in neonatal mass screening. Clin Chem 22(7):1001\u20131004","journal-title":"Clin Chem"},{"issue":"1\u20132","key":"2_CR18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0009-8981(82)90117-6","volume":"123","author":"A Grenier","year":"1982","unstructured":"Grenier A, Lescault A, Laberge C, Gagne R, Mamer O (1982) Detection of succinylacetone and the use of its measurement in mass screening for hereditary tyrosinemia. Clin Chim Acta 123(1\u20132):93\u201399","journal-title":"Clin Chim Acta"},{"issue":"3","key":"2_CR19","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/(SICI)1097-0223(199603)16:3<239::AID-PD829>3.0.CO;2-W","volume":"16","author":"A Grenier","year":"1996","unstructured":"Grenier A, Cederbaum S, Laberge C, Gagne R, Jakobs C, Tanguay RM (1996) A case of tyrosinaemia type I with normal level of succinylacetone in the amniotic fluid. Prenat Diagn 16(3):239\u2013242. doi:10.1002\/(SICI)1097-0223(199603)16:3<239::AID-PD829>3.0.CO;2-W","journal-title":"Prenat Diagn"},{"issue":"1","key":"2_CR20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/humu.1380050117","volume":"5","author":"M Grompe","year":"1995","unstructured":"Grompe M, Al-Dhalimy M (1995) Rapid nonradioactive assay for the detection of the common French Canadian tyrosinemia type I mutation. Hum Mutat 5(1):105. doi: 10.1002\/humu.1380050117","journal-title":"Hum Mutat"},{"issue":"6","key":"2_CR21","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1056\/NEJM199408113310603","volume":"331","author":"M Grompe","year":"1994","unstructured":"Grompe M, St-Louis M, Demers SI, al-Dhalimy M, Leclerc B, Tanguay RM (1994) A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I. N Engl J Med 331(6):353\u2013357. doi: 10.1056\/NEJM199408113310603","journal-title":"N Engl J Med"},{"issue":"5","key":"2_CR22","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1136\/jmg.35.5.366","volume":"35","author":"AC Hutchesson","year":"1998","unstructured":"Hutchesson AC, Bundey S, Preece MA, Hall SK, Green A (1998) A comparison of disease and gene frequencies of inborn errors of metabolism among different ethnic groups in the West Midlands, UK. J Med Genet 35(5):366\u2013370","journal-title":"J Med Genet"},{"issue":"2","key":"2_CR23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/pd.1970100210","volume":"10","author":"C Jakobs","year":"1990","unstructured":"Jakobs C, Stellaard F, Kvittingen EA, Henderson M, Lilford R (1990) First-trimester prenatal diagnosis of tyrosinemia type I by amniotic fluid succinylacetone determination. Prenat Diagn 10(2):133\u2013134","journal-title":"Prenat Diagn"},{"issue":"1","key":"2_CR24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1006\/bbrc.1997.6220","volume":"232","author":"R Jorquera","year":"1997","unstructured":"Jorquera R, Tanguay RM (1997) The mutagenicity of the tyrosine metabolite, fumarylacetoacetate, is enhanced by glutathione depletion. Biochem Biophys Res Commun 232(1):42\u201348. (47). doi: http:\/\/dx.doi.org\/10.1006\/bbrc.1997.6220","journal-title":"Biochem Biophys Res Commun"},{"issue":"17","key":"2_CR25","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1093\/hmg\/10.17.1741","volume":"10","author":"R Jorquera","year":"2001","unstructured":"Jorquera R, Tanguay RM (2001) Fumarylacetoacetate, the metabolite accumulating in hereditary tyrosinemia, activates the ERK pathway and induces mitotic abnormalities and genomic instability. Hum Mol Genet 10(17):1741\u20131752","journal-title":"Hum Mol Genet"},{"issue":"10","key":"2_CR26","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/BF02830839","volume":"71","author":"D Karnik","year":"2004","unstructured":"Karnik D, Thomas N, Eapen CE, Jana AK, Oommen A (2004) Tyrosinemia type I: a clinico-laboratory case report. Indian J Pediatr 71(10):929\u2013932","journal-title":"Indian J Pediatr"},{"issue":"3","key":"2_CR27","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0009-8981(81)90244-8","volume":"115","author":"EA Kvittingen","year":"1981","unstructured":"Kvittingen EA, Jellum E, Stokke O (1981) Assay of fumarylacetoacetate fumarylhydrolase in human liver-deficient activity in a case of hereditary tyrosinemia. Clin Chim Acta 115(3):311\u2013319","journal-title":"Clin Chim Acta"},{"issue":"7","key":"2_CR28","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1203\/00006450-198307000-00005","volume":"17","author":"EA Kvittingen","year":"1983","unstructured":"Kvittingen EA, Halvorsen S, Jellum E (1983) Deficient fumarylacetoacetate fumarylhydrolase activity in lymphocytes and fibroblasts from patients with hereditary tyrosinemia. Pediatr Res 17(7):541\u2013544. doi: 10.1203\/00006450-198307000-00005","journal-title":"Pediatr Res"},{"issue":"4","key":"2_CR29","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1172\/JCI116393","volume":"91","author":"EA Kvittingen","year":"1993","unstructured":"Kvittingen EA, Rootwelt H, Brandtzaeg P, Bergan A, Berger R (1993) Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect. J Clin Invest 91(4):1816\u20131821. doi: 10.1172\/JCI116393","journal-title":"J Clin Invest"},{"issue":"4","key":"2_CR30","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1172\/JCI117509","volume":"94","author":"EA Kvittingen","year":"1994","unstructured":"Kvittingen EA, Rootwelt H, Berger R, Brandtzaeg P (1994) Self-induced correction of the genetic defect in tyrosinemia type I. J Clin Invest 94(4):1657\u20131661. doi: 10.1172\/JCI117509","journal-title":"J Clin Invest"},{"issue":"3","key":"2_CR31","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.toxlet.2006.10.027","volume":"168","author":"SA Langie","year":"2007","unstructured":"Langie SA, Knaapen AM, Houben JM, van Kempen FC, de Hoon JP, Gottschalk RW, Godschalk RW, van Schooten FJ (2007) The role of glutathione in the regulation of nucleotide excision repair during oxidative stress. Toxicol Lett 168(3):302\u2013309. doi:S0378-4274(06)01335-X","journal-title":"Toxicol Lett"},{"issue":"3","key":"2_CR32","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ymgme.2007.09.018","volume":"93","author":"C Langlois","year":"2008","unstructured":"Langlois C, Jorquera R, Orejuela D, Bergeron A, Finegold MJ, Rhead WJ, Tanguay RM (2008) Rescue from neonatal death in the murine model of hereditary tyrosinemia by glutathione monoethylester and vitamin C treatment. Mol Genet Metab 93(3):306\u2013313. doi:S1096-7192(07)00441-6","journal-title":"Mol Genet Metab"},{"issue":"1\u20132","key":"2_CR33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2012.05.022","volume":"107","author":"J Larochelle","year":"2012","unstructured":"Larochelle J, Alvarez F, Bussieres JF, Chevalier I, Dallaire L, Dubois J, Faucher F, Fenyves D, Goodyer P, Grenier A, Holme E, Laframboise R, Lambert M, Lindstedt S, Maranda B, Melancon S, Merouani A, Mitchell J, Parizeault G, Pelletier L, Phan V, Rinaldo P, Scott CR, Scriver C, Mitchell GA (2012) Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Quebec. Mol Genet Metab 107(1\u20132):49\u201354. doi:S1096-7192(12)00211-9","journal-title":"Mol Genet Metab"},{"key":"2_CR34","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/B978-0-08-046884-6.00119-6","volume-title":"Comprehensive toxicology","author":"O Lee","year":"2010","unstructured":"Lee O, O\u2019Brien PJ (2010) Modifications of mitochondrial function by toxicants. In: CA MQ (ed) Comprehensive toxicology. Elsevier, Oxford, pp 411\u2013445"},{"issue":"10","key":"2_CR35","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1073\/pnas.74.10.4641","volume":"74","author":"B Lindblad","year":"1977","unstructured":"Lindblad B, Lindstedt S, Steen G (1977) On the enzymic defects in hereditary tyrosinemia. Proc Natl Acad Sci U S A 74(10):4641\u20134645","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8823","key":"2_CR36","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/0140-6736(92)92685-9","volume":"340","author":"S Lindstedt","year":"1992","unstructured":"Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B (1992) Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 340(8823):813\u2013817. doi:0140-6736(92)92685-9","journal-title":"Lancet"},{"issue":"6","key":"2_CR37","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2165\/00003495-200666060-00002","volume":"66","author":"PJ McKiernan","year":"2006","unstructured":"McKiernan PJ (2006) Nitisinone in the treatment of hereditary tyrosinaemia type 1. Drugs 66(6):743\u2013750. doi:6662","journal-title":"Drugs"},{"key":"2_CR38","first-page":"1777","volume-title":"The metabolic and molecular bases of inherited diseases","author":"GA Mitchell","year":"2001","unstructured":"Mitchell GA, Grompe M, Lambert H, Tanguay RM (2001) Hypertyrosinemia. In: Scriver C, Beaudet A, Sly WSJ, Valle D (eds) The metabolic and molecular bases of inherited diseases, vol II, 8th edn. McGrawHill, New York, pp 1777\u20131805","edition":"8th"},{"issue":"Suppl 2","key":"2_CR39","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1007\/PL00014321","volume":"158","author":"N Mohan","year":"1999","unstructured":"Mohan N, McKiernan P, Preece MA, Green A, Buckels J, Mayer AD, Kelly DA (1999) Indications and outcome of liver transplantation in tyrosinaemia type 1. Eur J Pediatr 158(Suppl 2):S49\u2013S54. doi:9158S049.431","journal-title":"Eur J Pediatr"},{"issue":"10","key":"2_CR40","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/(SICI)1097-0223(199710)17:10<964::AID-PD164>3.0.CO;2-6","volume":"17","author":"A Mustonen","year":"1997","unstructured":"Mustonen A, Ploos van Amstel HK, Berger R, Salo MK, Viinikka L, Simola KO (1997) Mutation analysis for prenatal diagnosis of hereditary tyrosinaemia type 1. Prenat Diagn 17(10):964\u2013966. doi:10.1002\/(SICI)1097-0223(199710)17:10<964::AID-PD164>3.0.CO;2-6","journal-title":"Prenat Diagn"},{"issue":"19","key":"2_CR41","doi-asserted-by":"crossref","first-page":"9297","DOI":"10.1073\/pnas.89.19.9297","volume":"89","author":"E Natt","year":"1992","unstructured":"Natt E, Kida K, Odievre M, Di Rocco M, Scherer G (1992) Point mutations in the tyrosine aminotransferase gene in tyrosinemia type II. Proc Natl Acad Sci U S A 89(19):9297\u20139301","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2_CR42","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0009-8981(77)90161-9","volume":"76","author":"A Niederwieser","year":"1977","unstructured":"Niederwieser A, Matasovic A, Tippett P, Danks DM (1977) A new sulfur amino acid, named hawkinsin, identified in a baby with transient tyrosinemia and her mother. Clin Chim Acta 76(3):345\u2013356","journal-title":"Clin Chim Acta"},{"issue":"2","key":"2_CR43","first-page":"338","volume":"47","author":"K Paradis","year":"1990","unstructured":"Paradis K, Weber A, Seidman EG, Larochelle J, Garel L, Lenaerts C, Roy CC (1990) Liver transplantation for hereditary tyrosinemia: the Quebec experience. Am J Hum Genet 47(2):338\u2013342","journal-title":"Am J Hum Genet"},{"issue":"3","key":"2_CR44","first-page":"525","volume":"48","author":"D Phaneuf","year":"1991","unstructured":"Phaneuf D, Labelle Y, Berube D, Arden K, Cavenee W, Gagne R, Tanguay RM (1991) Cloning and expression of the cDNA encoding human fumarylacetoacetate hydrolase, the enzyme deficient in hereditary tyrosinemia: assignment of the gene to chromosome 15. Am J Hum Genet 48(3):525\u2013535","journal-title":"Am J Hum Genet"},{"issue":"4","key":"2_CR45","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1172\/JCI115979","volume":"90","author":"D Phaneuf","year":"1992","unstructured":"Phaneuf D, Lambert M, Laframboise R, Mitchell G, Lettre F, Tanguay RM (1992) Type 1 hereditary tyrosinemia. Evidence for molecular heterogeneity and identification of a causal mutation in a French Canadian patient. J Clin Invest 90(4):1185\u20131192. doi: 10.1172\/JCI115979","journal-title":"J Clin Invest"},{"issue":"6","key":"2_CR46","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s10545-005-0059-0","volume":"28","author":"LJ Pierik","year":"2005","unstructured":"Pierik LJ, van Spronsen FJ, Bijleveld CM, van Dael CM (2005) Renal function in tyrosinaemia type I after liver transplantation: a long-term follow-up. J Inherit Metab Dis 28(6):871\u2013876. doi: 10.1007\/s10545-005-0059-0","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"2_CR47","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/(SICI)1097-0223(199601)16:1<59::AID-PD810>3.0.CO;2-D","volume":"16","author":"J Poudrier","year":"1996","unstructured":"Poudrier J, St-Louis M, Lettre F, Gibson K, Prevost C, Larochelle J, Tanguay RM (1996) Frequency of the IVS12 + 5G-->A splice mutation of the fumarylacetoacetate hydrolase gene in carriers of hereditary tyrosinaemia in the French Canadian population of Saguenay-Lac-St-Jean. Prenat Diagn 16(1):59\u201364. doi:10.1002\/(SICI)1097-0223(199601)16:1<59::AID-PD810>3.0.CO;2-D","journal-title":"Prenat Diagn"},{"issue":"2","key":"2_CR48","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1006\/mgme.1998.2695","volume":"64","author":"J Poudrier","year":"1998","unstructured":"Poudrier J, Lettre F, Scriver CR, Larochelle J, Tanguay RM (1998) Different clinical forms of hereditary tyrosinemia (type I) in patients with identical genotypes. Mol Genet Metab 64(2):119\u2013125. doi:S1096-7192(98)92695-6","journal-title":"Mol Genet Metab"},{"issue":"2\u20133","key":"2_CR49","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0925-4439(01)00041-2","volume":"1536","author":"DR Richardson","year":"2001","unstructured":"Richardson DR, Mouralian C, Ponka P, Becker E (2001) Development of potential iron chelators for the treatment of Friedreich\u2019s ataxia: ligands that mobilize mitochondrial iron. Biochim Biophys Acta 1536(2\u20133):133\u2013140","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"2_CR50","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3181\/00379727-196-43211","volume":"196","author":"KS Roth","year":"1991","unstructured":"Roth KS, Carter BE, Higgins ES (1991) Succinylacetone effects on renal tubular phosphate metabolism: a model for experimental renal Fanconi syndrome. Proc Soc Exp Biol Med 196(4):428\u2013431","journal-title":"Proc Soc Exp Biol Med"},{"issue":"2","key":"2_CR51","first-page":"317","volume":"47","author":"P Russo","year":"1990","unstructured":"Russo P, O\u2019Regan S (1990) Visceral pathology of hereditary tyrosinemia type I. Am J Hum Genet 47(2):317\u2013324","journal-title":"Am J Hum Genet"},{"issue":"3","key":"2_CR52","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s100240010146","volume":"4","author":"PA Russo","year":"2001","unstructured":"Russo PA, Mitchell GA, Tanguay RM (2001) Tyrosinemia: a review. Pediatr Dev Pathol 4(3):212\u2013221","journal-title":"Pediatr Dev Pathol"},{"issue":"4","key":"2_CR53","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3978\/j.issn.2224-4336.2015.10.08","volume":"4","author":"DA Schady","year":"2015","unstructured":"Schady DA, Roy A, Finegold MJ (2015) Liver tumors in children with metabolic disorders. Transl Pediatr 4(4):290\u2013303. doi: 10.3978\/j.issn.2224-4336.2015.10.08","journal-title":"Transl Pediatr"},{"key":"2_CR54","unstructured":"Sniderman King L, Trahms C, Scott CR (2006 ) Tyrosinemia type 1. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, Stephens K (eds). doi: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1515\/"},{"issue":"4","key":"2_CR55","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/(SICI)1098-1004(1997)9:4<291::AID-HUMU1>3.0.CO;2-9","volume":"9","author":"M St-Louis","year":"1997","unstructured":"St-Louis M, Tanguay RM (1997) Mutations in the fumarylacetoacetate hydrolase gene causing hereditary tyrosinemia type I: overview. Hum Mutat 9(4):291\u2013299. doi:10.1002\/(SICI)1098-1004(1997)9:4<291::AID-HUMU1>3.0.CO;2-9","journal-title":"Hum Mutat"},{"issue":"1","key":"2_CR56","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/hmg\/3.1.69","volume":"3","author":"M St-Louis","year":"1994","unstructured":"St-Louis M, Leclerc B, Laine J, Salo MK, Holmberg C, Tanguay RM (1994) Identification of a stop mutation in five Finnish patients suffering from hereditary tyrosinemia type I. Hum Mol Genet 3(1):69\u201372","journal-title":"Hum Mol Genet"},{"issue":"1","key":"2_CR57","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2174\/1874467211205010088","volume":"5","author":"SJ Storr","year":"2012","unstructured":"Storr SJ, Woolston CM, Martin SG (2012) Base excision repair, the redox environment and therapeutic implications. Curr Mol Pharmacol 5(1):88\u2013101. doi:EPub-Abstract-CMP-60","journal-title":"Curr Mol Pharmacol"},{"key":"2_CR58","volume-title":"Fumarylacetoacetate hydrolase. Wiley encyclopedia of molecular medicine","author":"R Tanguay","year":"2002","unstructured":"Tanguay R (2002) Fumarylacetoacetate hydrolase. Wiley encyclopedia of molecular medicine. Wiley, New York"},{"issue":"2","key":"2_CR59","first-page":"308","volume":"47","author":"RM Tanguay","year":"1990","unstructured":"Tanguay RM, Valet JP, Lescault A, Duband JL, Laberge C, Lettre F, Plante M (1990) Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I). Am J Hum Genet 47(2):308\u2013316","journal-title":"Am J Hum Genet"},{"issue":"1","key":"2_CR60","doi-asserted-by":"crossref","first-page":"209","DOI":"10.18388\/abp.1996_4530","volume":"43","author":"RM Tanguay","year":"1996","unstructured":"Tanguay RM, Jorquera R, Poudrier J, St-Louis M (1996) Tyrosine and its catabolites: from disease to cancer. Acta Biochim Pol 43(1):209\u2013216","journal-title":"Acta Biochim Pol"},{"key":"2_CR61","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/B978-0-12-449851-8.00040-1","volume-title":"Genetic diseases of the kidney, vol Chap 40","author":"RM Tanguay","year":"2009","unstructured":"Tanguay RM, Bergeron A, Jorquera R (2009) Hepatorenal tyrosinemia. In: Lifton RP, Somlo S, Giebsih D, Seldin DW (eds) Genetic diseases of the kidney, vol Chap 40. Elsevier, Amsterdam, pp 681\u2013691"},{"issue":"9","key":"2_CR62","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0969-2126(99)80170-1","volume":"7","author":"DE Timm","year":"1999","unstructured":"Timm DE, Mueller HA, Bhanumoorthy P, Harp JM, Bunick GJ (1999) Crystal structure and mechanism of a carbon-carbon bond hydrolase. Structure 7(9):1023\u20131033. doi:st7915","journal-title":"Structure"},{"issue":"3","key":"2_CR63","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1006\/mgme.2000.3085","volume":"71","author":"K Tomoeda","year":"2000","unstructured":"Tomoeda K, Awata H, Matsuura T, Matsuda I, Ploechl E, Milovac T, Boneh A, Scott CR, Danks DM, Endo F (2000) Mutations in the 4-hydroxyphenylpyruvic acid dioxygenase gene are responsible for tyrosinemia type III and hawkinsinuria. Mol Genet Metab 71(3):506\u2013510. doi: 10.1006\/mgme.2000.3085","journal-title":"Mol Genet Metab"},{"issue":"3","key":"2_CR64","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0022-3476(87)80501-2","volume":"110","author":"M Tuchman","year":"1987","unstructured":"Tuchman M, Freese DK, Sharp HL, Ramnaraine ML, Ascher N, Bloomer JR (1987) Contribution of extrahepatic tissues to biochemical abnormalities in hereditary tyrosinemia type I: study of three patients after liver transplantation. J Pediatr 110(3):399\u2013403","journal-title":"J Pediatr"},{"issue":"1","key":"2_CR65","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.bbrc.2010.09.002","volume":"401","author":"E Dyk van","year":"2010","unstructured":"van Dyk E, Steenkamp A, Koekemoer G, Pretorius PJ (2010) Hereditary tyrosinemia type 1 metabolites impair DNA excision repair pathways. Biochem Biophys Res Commun 401(1):32\u201336. doi:S0006-291X(10)01677-3","journal-title":"Biochem Biophys Res Commun"},{"issue":"Suppl 2","key":"2_CR66","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/BF03335416","volume":"12","author":"FJ Spronsen van","year":"1989","unstructured":"van Spronsen FJ, Berger R, Smit GP, de Klerk JB, Duran M, Bijleveld CM, van Faassen H, Slooff MJ, Heymans HS (1989) Tyrosinaemia type I: orthotopic liver transplantation as the only definitive answer to a metabolic as well as an oncological problem. J Inherit Metab Dis 12(Suppl 2):339\u2013342","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"2_CR67","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/hep.1840200513","volume":"20","author":"FJ Spronsen van","year":"1994","unstructured":"van Spronsen FJ, Thomasse Y, Smit GP, Leonard JV, Clayton PT, Fidler V, Berger R, Heymans HS (1994) Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. Hepatology 20(5):1187\u20131191. doi:S027091399400340X","journal-title":"Hepatology"},{"issue":"1","key":"2_CR68","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/00005176-200501000-00017","volume":"40","author":"FJ Spronsen van","year":"2005","unstructured":"van Spronsen FJ, Bijleveld CM, van Maldegem BT, Wijburg FA (2005) Hepatocellular carcinoma in hereditary tyrosinemia type I despite 2-(2 nitro-4-3 trifluoro- methylbenzoyl)-1, 3-cyclohexanedione treatment. J Pediatr Gastroenterol Nutr 40(1):90\u201393. doi:00005176-200501000-00017","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"12","key":"2_CR69","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1002\/humu.21120","volume":"30","author":"T Vilboux","year":"2009","unstructured":"Vilboux T, Kayser M, Introne W, Suwannarat P, Bernardini I, Fischer R, O\u2019Brien K, Kleta R, Huizing M, Gahl WA (2009) Mutation spectrum of homogentisic acid oxidase (HGD) in alkaptonuria. Hum Mutat 30(12):1611\u20131619. doi: 10.1002\/humu.21120","journal-title":"Hum Mutat"},{"issue":"3","key":"2_CR70","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0022-3476(76)80259-4","volume":"88","author":"AG Weinberg","year":"1976","unstructured":"Weinberg AG, Mize CE, Worthen HG (1976) The occurrence of hepatoma in the chronic form of hereditary tyrosinemia. J Pediatr 88(3):434\u2013438","journal-title":"J Pediatr"},{"issue":"15","key":"2_CR71","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1056\/NEJM198110083051505","volume":"305","author":"B Wilcken","year":"1981","unstructured":"Wilcken B, Hammond JW, Howard N, Bohane T, Hocart C, Halpern B (1981) Hawkinsinuria: a dominantly inherited defect of tyrosine metabolism with severe effects in infancy. N Engl J Med 305(15):865\u2013868. doi: 10.1056\/NEJM198110083051505","journal-title":"N Engl J Med"},{"issue":"1","key":"2_CR72","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1042\/cs0830081","volume":"83","author":"PA Wyss","year":"1992","unstructured":"Wyss PA, Boynton SB, Chu J, Spencer RF, Roth KS (1992) Physiological basis for an animal model of the renal Fanconi syndrome: use of succinylacetone in the rat. Clin Sci 83(1):81\u201387","journal-title":"Clin Sci"}],"container-title":["Advances in Experimental Medicine and Biology","Hereditary Tyrosinemia"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-55780-9_2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T21:07:10Z","timestamp":1719349630000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-319-55780-9_2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9783319557793","9783319557809"],"references-count":72,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-55780-9_2","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}